India, Nov. 13 -- Novo Nordisk (NVO,NOVOB.CO,NOV.DE) has received European Commission marketing authorization for FREHEMGO (denecimig), a next-generation therapy for the routine prophylaxis of bleeding episodes in adults and children with haemophilia A, with or without inhibitors.
The approval marks a significant milestone for the company and expands treatment options for people living with haemophilia A, a rare inherited bleeding disorder caused by a deficiency of clotting factor VIII (FVIII). Patients with the condition face an increased risk of spontaneous and prolonged bleeding, which can lead to joint damage and other serious complications if not adequately controlled.
FREHEMGO is a factor VIIIa mimetic bispecific antibody administer...